ArticleRespirology case reports2025
An Uncommon Case of Non-Specific Interstitial Pneumonia (NSIP) Associated With Idiopathic Hypereosinophilic Syndrome (HES) Reversed by Mepolizumab.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Most Promising Emerging Therapies for Pulmonary Fibrosis: Targeting Novel Pathways.Biomedicines · 2026Review
- An Uncommon Case of Non-Specific Interstitial Pneumonia (NSIP) Associated With Idiopathic Hypereosinophilic Syndrome (HES) Reversed by Mepolizumab.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypereosinophilic Syndrome (HES) represents a heterogeneous and complex group of disorders characterised by persistent blood and tissue eosinophilia, leading to progressive tissue damage and organ dysfunction. This spectrum includes both hematologic variants and non-hematologic forms, either secondary to identifiable causes or idiopathic in nature. In this article, we describe a rare clinical presentation of HES manifesting primarily with pulmonary involvement, diagnosed as Non-Specific Interstitial Pneumonia (NSIP). Remarkably, the interstitial lung disease showed near-complete reversibility following targeted inhibition of the IL-5 pathway with mepolizumab, highlighting the potential role of Th2-driven eosinophilic inflammation in the pathogenesis of certain forms of interstitial lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.